Drug Profile


Alternative Names: RYI-018

Latest Information Update: 26 Jan 2017

Price : $50

At a glance

  • Originator Bird Rock Bio
  • Class Monoclonal antibodies
  • Mechanism of Action Cannabinoid receptor CB1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Most Recent Events

  • 11 Jan 2017 Bird Rock Bio receives IND approval for namacizumab in Non-alcoholic fatty liver disease
  • 27 Oct 2016 Bird Rock Bio files Clinical Trial Application for namacizumab for Non-alcoholic fatty liver disease
  • 14 Dec 2015 Bird Rock Bio plans a phase I trial for namacizumab for Non-alcoholic fatty liver disease in USA, New Zealand and Australia (ACTRN12617000133336; 9189024; 9205865)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top